Articles dans des revues avec comité de lecture (164)

  1. 102. Zouaoui Boudjeltia, K., Faraut, B., Esposito, M. J., Stenuit, P., Dyzma, M., Van Antwerpen, P., Brohée, D., Vanhamme, L., Moguilevsky, N., Vanhaeverbeek, M., & Kerkhofs, M. (2011). Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men. PloS one, 6(11), e28230. doi:10.1371/journal.pone.0028230
  2. 103. Soubhye, J., Prévost, M., Van Antwerpen, P., Zouaoui Boudjeltia, K., Rousseau, A., Furtmüller, P. G., Obinger, C., Vanhaeverbeek, M., Ducobu, J., Neve, J., Gelbcke, M., & Dufrasne, F. (2010). Structure-based design, synthesis, and pharmacological evaluation of 3-(Aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. Journal of medicinal chemistry, 53(24), 8747-8759. doi:10.1021/jm1009988
  3. 104. Calay, D., Rousseau, A., Mattart, L., Nuyens, V., Delporte, C., Van Antwerpen, P., Moguilevsky, N., Arnould, T., Zouaoui Boudjeltia, K., & Raes, M. (2010). Copper and myeloperoxidase-modified LDLs activate Nrf2 through different pathways of ROS production in macrophages. Antioxidants & redox signalling, 13(10), 1491-1502. doi:10.1089/ars.2009.2971
  4. 105. Cheel, J., Van Antwerpen, P., Tumova, L., Onofre, G., Vokurkova, D., Zouaoui Boudjeltia, K., Vanhaeverbeek, M., & Neve, J. (2010). Free radical-scavenging, antioxidant and immunostimulating effects of a licorice infusion (Glycyrrhiza glabra L.). Food chemistry, 122(3), 508-517.
  5. 106. Faraut, B., Zouaoui Boudjeltia, K., Dyzma, M., Rousseau, A., David, E., Stenuit, P., Franck, T., Van Antwerpen, P., Vanhaeverbeek, M., & Kerkhofs, M. (2010). Benefits of napping and an extended duration of recovery sleep on alertness and immune cells after acute sleep restriction. Brain, behavior, and immunity, 25, 16-24. doi:10.1016/j.bbi.2010.08.001
  6. 107. Delporte, C., Van Antwerpen, P., Zouaoui Boudjeltia, K., Noyon, C., Calay, D., Reye, F., Rousseau, A., Raes, M., Vanhaeverbeek, M., Ducobu, J., & Neve, J. (2010). Specific oxidation of apolipoprotein-B-100 by myeloperoxidase. Atherosclerosis. Supplement, 11(2).
  7. 108. Dyzma, M., Zouaoui Boudjeltia, K., Faraut, B., & Kerkhofs, M. (2010). Neuropeptide Y and sleep. Sleep medicine reviews, 14(3), 161-165. doi:10.1016/j.smrv.2009.09.001
  8. 109. Van Antwerpen, P., Zouaoui Boudjeltia, K., Furtmüller, P. G., Dieu, M., Delporte, C., Raes, M., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., Neve, J., & Obinger, C. (2010). Oxidation of cyanide to cyanate by myeloperoxidase: A new route for apolipoprotein carbamylation? Atherosclerosis. Supplement, 11(2).
  9. 110. Van Antwerpen, P., Slomianny, M.-C., Zouaoui Boudjeltia, K., Delporte, C., Faid, V., Calay, D., Rousseau, A., Moguilevsky, N., Raes, M., Vanhamme, L., Furtmüller, P. G., Obinger, C., Vanhaeverbeek, M., Neve, J., & Michalski, J.-C. (2010). Glycosylation pattern of mature dimeric leukocyte and recombinant monomeric myeloperoxidase: glycosylation is required for optimal enzymatic activity. The Journal of biological chemistry, 285(21), 16351-16359. doi:10.1074/jbc.M109.089748
  10. 111. Zouaoui Boudjeltia, K., Durez, P., Oberweis, D., Guillaume, M., Remacle, C., Cauchie, P., Vanhaeverbeek, M., Brohée, D., Ducobu, J., & Gregoir, C. (2010). Effects of raloxifene treatment on the phenotype of blood monocytes. Canadian journal of physiology and pharmacology, 88(5), 601-605. doi:10.1139/y10-002
  11. 112. Roumeguere, T., Zouaoui Boudjeltia, K., Babar, S., Nuyens, V., Rousseau, A., Van Antwerpen, P., Ducobu, J., Wespes, E., & Vanhaeverbeek, M. (2010). Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. European urology, 57(3), 522-528. doi:10.1016/j.eururo.2009.01.030
  12. 113. Lelubre, C., Zouaoui Boudjeltia, K., Van Antwerpen, P., Vanhaeverbeek, M., & Roumeguere, T. (2010). Phosphodiesterase Inhibitors in the Treatment of Inflammatory Disorders: A Narrative Review. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(2), 1-15.

  13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Suivant >>